Quantitative determination of puerarin in dog plasma by HPLC and study on the relative bioavailability of sustained release tablets

Ren, Fuzheng; Jing, Qiufang; Shen, Yongjia; Ma, Hongmei; Jingbin, Cui

doi:10.1016/j.jpba.2005.11.041

Cited by 40 publications

(36 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concentration of puerarin in serum (mean C max = 3.54 mg/L) may be accounted for by its lower tissue distribution compared with those reported for other isoflavones in previous studies (Setchell et al, 2001). The terminal half-life (T 1/2 ) of puerarin in our studies (1.70 h) was found to be similar to that previously reported (1.52 h) for puerarin YU-tablet in dog plasma (Ren et al, 2006). The mean T max of puerarin in this study was in close agreement with the published report (Li et al, 2006) …”

Section: Pharmacokinetic Studysupporting

confidence: 87%

See 1 more Smart Citation

Pharmacokinetic study of puerarin in rat serum by liquid chromatography tandem mass spectrometry

Prasain

Peng

Acosta

et al. 2007

Biomedical Chromatography

View full text Add to dashboard Cite

A highly sensitive and specific atmospheric pressure chemical ionization liquid chromatography-tandem mass spectrometry method was developed for serum pharmacokinetic studies of puerarin in rats. Chromatography was carried out on a reversed-phase Phenomenex Synergi 4 microm Fusion-RP80 column (150 x 2.0 mm i.d.) using a mobile phase consisting of acetonitrile-water (10:90, v/v) in 10 mm NH(4)OAc with a flow rate of 0.2 mL/min. Puerarin was analyzed in the multiple reaction monitoring mode with a precursor/product ion transition of m/z 415/267. The method was demonstrated to be specific and sensitive, and a linear response was observed over a range of 2-5000 ng/mL in rat serum. The validated method was successfully applied to the characterization of the pharmacokinetics of puerarin in rat serum after oral administration to spontaneously hypertensive rats. The blood concentration-time profile of puerarin showed a rapid initial increase, reaching a maximum and then declining within 1 h. Puerarin could not be detected after 24 h. The main pharmacokinetic parameters for puerarin after oral administration were as follows: C(max) (3.54 +/- 2.03 mg/L), T(max) (0.68 +/- 0.37 h), AUC(0-t) (7.29 +/- 3.79 mg h/L), AUC(0-infinity) (9.17 +/- 4.87 mg h/L), T(1/2) (1.7 +/- 0.6 h), CL/F (7.24 +/- 4.27 L/h/kg) and V/F (17.88 +/- 13.55 L/h/kg).

show abstract

Section: Pharmacokinetic Studysupporting

confidence: 87%

“…Previous methods of analyzing puerarin in biological samples are based on HPLC-UV (Ren et al, 2006;Ma et al, 2005;Li et al, 2006). To our knowledge, no publication describing a pharmacokinetic study of puerarin in rat serum using liquid chromatography tandem mass spectrometry (LC-MS/MS) has been reported until now.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic study of puerarin in rat serum by liquid chromatography tandem mass spectrometry

Prasain

Peng

Acosta

et al. 2007

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…The presence of intact aspalathin in urine suggests that the efficacy of existing plasma extraction protocols may not be suitable for the analysis of circulating C-glycosyl flavonoids, possibly due to the intact glucosylated structure having greater affinity for plasma carrier proteins such as serum albumin. This assertion is supported by the identification of intact puerarin, a non-dietary Cglucosyl isoflavone from kudzu root (Pueraria lobata), in the plasma of humans, rats and dogs (Ma et al, 2005;Ren et al, 2006;Shen et al, 2007). Despite these findings, the authors of a similar study reported the absence of C-glycosyl flavonoids in the collected urine or plasma of Sprague Dawley rats (n = 4) at any point in the 72 hr following a high, single-dose oral administration of 1 g kg -1 bamboo leaf extract in water (100 mg ml -1 ) containing the four flavone C-glycosides orientin, isoorientin, vitexin and isovitexin.…”

Section: The Biological Fate Of C-glycosyl Flavonoids In the Human Dietmentioning

confidence: 93%

The Occurrence, Fate and Biological Activities ofC-glycosyl Flavonoids in the Human Diet

Courts

Williamson

2013

Critical Reviews in Food Science and Nutrition

View full text Add to dashboard Cite

“…Ohwi, which is used in the treatment of cardiovascular diseases, such as coronary heart disease, cardiac infarction, arteriosclerosis and arrhythmia (Ren et al, 2006;Yeung et al, 2006). However, it was reported that oral bioavailability of PUE was just approximately 4%, the cumulative excretion rate of unchanged PUE in urine and feces was 45.33% in 24 h and most of it was mainly excreted by dejection (Gou et al, 2006;Luo et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

N-trimethyl chitosan (TMC)-modified microemulsions for improved oral bioavailability of puerarin: preparation and evaluation

et al. 2014

View full text Add to dashboard Cite

The aim of this research was to increase the oral bioavailability of puerarin by N-trimethyl chitosan-modified microemulsions (TMC-MEs) loaded with puerarin. Different concentrations of TMC-modified microemulsions were prepared in our study, and then evaluated for particle size, zeta potential, morphological observation and changes of the microenvironment polarity of inner oil core. It was shown that the zeta potential of the microemulsion was increased with the increasing concentration of TMC, and the peak value was achieved when the concentration of TMC was 3.0 mg/mL. The enhancement of the ratio of I 1 /I 3 (the ratio between the first band and the third band of the emission fluorescence spectrum of pyrene, I 1 ¼ 373 nm, I 3 ¼ 384 nm) indicated that polarity of the inner core of TMC-MEs was increased with the addition of the modifier. Pharmacokinetic studies demonstrated that after oral administration of puerarin N-trimethyl chitosan (TMC)-modified microemulsions (PUE-TMEs) and puerarin microemulsions (PUE-MEs) to rats at a dose of 100 mg/kg, relative bioavailability was enhanced about 6.8-and 1.2-fold, respectively, compared to puerarin suspension (PUE-SUS) as control. It indicated that the TMC-MEs could be used as an effective formulation for enhancing the oral bioavailability of puerarin.

show abstract

Quantitative determination of puerarin in dog plasma by HPLC and study on the relative bioavailability of sustained release tablets

Cited by 40 publications

References 5 publications

Pharmacokinetic study of puerarin in rat serum by liquid chromatography tandem mass spectrometry

Pharmacokinetic study of puerarin in rat serum by liquid chromatography tandem mass spectrometry

The Occurrence, Fate and Biological Activities ofC-glycosyl Flavonoids in the Human Diet

N-trimethyl chitosan (TMC)-modified microemulsions for improved oral bioavailability of puerarin: preparation and evaluation

Contact Info

Product

Resources

About